Larimar Therapeutics, Inc. (LRMR) stock
Close on Nov 11, 2026Market cap $283.60MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $283.60M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.23
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$172.61M
- Free cash flow
- -$113.29M
Trading
- Next earnings
- Mar 18, 2027 (estimated, before the open)
- Previous close
- $2.69
- Open
- $2.72
- Day's range
- $2.60 – $2.83
- Volume
- 1,157,190
- Average volume (20 days)
- 1,505,640
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 1.33
- 52-week range
- $1.92 – $6.42
- RSI (14 days)
- 53.0
- Volatility (1 year)
- 101.1%
- Relative volume
- 0.84×
- WACC
- 11.5%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | LRMR | S&P 500 | Difference | LRMR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +2.2% | -2.4% | +4.7 pts | ||
| 3 months | -36.7% | -1.2% | −35.5 pts | ||
| Year to date | -28.3% | +12.3% | −40.6 pts | ||
| 1 year | -24.8% | +12.4% | −37.2 pts | ||
| 3 years | +11.4% | +78.8% | −67.4 pts | +3.7% | +21.4% |
| 5 years | -78.2% | +75.2% | −153.3 pts | -26.2% | +11.9% |
| 10 years | -93.5% | +311.1% | −404.6 pts | -23.9% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Larimar Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- News
About Larimar Therapeutics
Pharmaceutical Preparations
The company is a clinical-stage biotechnology firm focused on developing novel treatments for patients suffering from complex, rare, and progressive genetic conditions. Its proprietary cell-penetrating peptide platform enables therapeutic molecules to traverse cellular and organellar membranes to deliver essential proteins to intracellular targets. The firm's lead investigational biologic candidate, nomlabofusp, delivers frataxin into mitochondria to address the underlying cellular deficit in individuals diagnosed with Friedreich's ataxia. Beyond its primary program, the organization works to apply its protein replacement platform across other rare orphan diseases caused by intracellular protein deficiencies.
Company profile, executives and historyLarimar Therapeutics stock: common questions
What is Larimar Therapeutics's stock price?
LRMR closed at $2.73 on Nov 11, 2026, up 1.49% on the day. Over the past 52 weeks it traded between $1.92 and $6.42.
What is Larimar Therapeutics's market cap?
Larimar Therapeutics was worth $283.60M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
Does Larimar Therapeutics pay a dividend?
No. Larimar Therapeutics has not paid a cash dividend over the last twelve months.
When does Larimar Therapeutics report earnings next?
Larimar Therapeutics is expected to report Q4 FY2026 results on Mar 18, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has LRMR stock performed over the past year?
Including dividends, LRMR returned -24.8% over the past year, against +12.4% for the S&P 500.
How many LRMR shares are sold short?
11M shares were sold short at the latest FINRA report, 30.14% of the float, or 8.3 days of average trading volume.
Who are Larimar Therapeutics's competitors?
Companies most similar to Larimar Therapeutics by business, industry and size include TRDA, KROS, KTTA, PTCT, PEPG.
See a number that looks wrong?